Assessment of 8-isoprostane (8-isoPGF2α) in Urine of Non-Small Cell Lung Cancer (NSCLC) Patients Undergoing Chemotherapy

  • Published : 2012.03.31


8-isoprostane (8-$isoPGF_{2{\alpha}}$) is a reliable marker and considered a gold standard for lipid peroxidation. There are very few reports of 8-isoprostane levels in cancer patients, and in patients undergoing chemotherapy. Oxidative stress is however expected and has been observed in patients with cancer. This study measured 8-isoprostane levels in urine by ELISA of 25 patients undergoing chemotherapy for advanced non-small cell lung cancer, at cycles 1, 2, and 3 of treatment. It considers the creatinine clearance of the patients, and correction of 8-isoprostane levels by creatinine clearance, and overnight urine volume methods. The average 8-isoprostane levels in urine increased more than 6 to 12 fold on chemotherapy treatment, from $532{\pm}587$ pg/mL at cycle $1,6181{\pm}4334$ at cycle 2, and $5511{\pm}2055$ at cycle 3. Similar results were obtained if 8-isoprostane levels were corrected for overnight urine volume, giving averages of $285{\pm}244{\mu}g$ at cycle $1,4122{\pm}3349$ at cycle 2, and $3266{\pm}1200$ at cycle 3. No significant difference was seen in average total overnight urine volume or number of urinations between chemotherapy cycles except for a large variation in urine volume between cycle 2 and 3. Creatinine levels were significantly different only between cycles 1 and 2 (p=0.016). In conclusion, cisplatin therapy has been shown to induce high levels of lipid peroxidation in lung cancer patients and can be assessed from the 8-isoprostane marker in overnight urine, with or without urine volume correction.


  1. Baek SM, Kwon CH, Kim JH, et al (2003). Differential roles of hydrogen peroxide and hydroxyl radical in cisplatin-induced cell death in renal proximal tubular epithelial cells. J Lab Clin Med, 142, 178-86.
  2. Barr DB, Wilder LC, Caudill SP, et al (2005). Urinary Creatinine Concentrations in the U.S. Population: Implications for Urinary Biologic Monitoring Measurements. Environ Health Perspect, 113, 192-200.
  3. Basu S (2008). $F_{2}$-isoprostanes in human health and diseases: from molecular mechanisms to clinical implications. Antioxid Redox Signal, 10, 1405-34.
  4. Chirinoa YI, Pedraza-Chaverri J (2009) Role of oxidative and nitrosative stress in cisplatin-induced nephrotoxicity. J Exper Tox Path, 61, 223-42
  5. Dalaveris E, Kerenidi T, Katsabeki-Katsafli A, et al (2009). VEGF, TNF-$\alpha$ and 8-isoprostane levels in exhaled breath condensate and serum of patients with lung cancer. Lung Cancer, 64, 219-25.
  6. Davies SS, Zackert W, Luo Y, et al (2006). Quantification of dinor, dihydro metabolites of $F_{2}$-isoprostanes in urine by liquid chromatography/tandem mass spectrometry. Anal Biochem, 348, 185-91.
  7. De Castro J, Hernandez-Hernandez A, Rodriguez MC, Llanillo M, Sanchez-Yague J (2006). Comparison of changes in erythrocyte and platelet fatty acid composition and protein oxidation in advanced non-small cell lung cancer. Cancer Invest, 24, 339-45.
  8. Fabbro ED, Dalal S, Bruera E (2006). Symptom Control in Palliative Care-Part II: Cachexia/Anorexia and Fatigue. J Pall Med, 9, 409-21.
  9. Garde AH, Hansen AM, Kristiansen J, Knudsen LE (2004). Comparison of Uncertainties Related to Standardization of Urine Samples with Volume and Creatinine Concentration. Ann Occup Hyg, 48, 171-9.
  10. Gupta A, Srivastava S, Prasad R, et al (2010). Oxidative stress in non-small cell lung cancer patients after chemotherapy: association with treatment response. Respirology, 15, 349- 56.
  11. Helmersson J, Basu S (1999). $F_{2}$-isoprostane excretion rate and diurnal variation in human urine. Prostaglandins Leukot Essent Fatty Acids, 61, 203-5.
  12. Il'yasova D, Kennedy K, Spasojevic I, et al (2010). Individual responses to chemotherapy-induced oxidative stress. Breast Cancer Res Treat, 125, 583-9.
  13. Janssen LJ (2001). Isoprostanes: an overview and putative roles in pulmonary pathophysiology. Am J Physiol Lung Cell Mol Physiol, 280, 1067-82.
  14. Janssen LJ (2008). Isoprostanes and lung vascular pathology. Am J Respir Cell Mol Biol, 39, 383-9.
  15. Kadiiska MB, Gladen BC, Baird DD, et al (2005). Biomarkers of oxidative stress study II: are oxidation products of lipids, proteins, and DNA markers of CCl4 poisoning? Free Radic Biol Med, 38, 698-710.
  16. Kannan K, Jain SK (2000). Oxidative stress and apoptosis. Pathophysiology, 7, 153-63.
  17. Liang Y, Wei P, Duke RW, et al (2003). Quantification of 8-isoprostaglandin- F(2alpha) and 2,3-dinor-8-iso-prostaglandin- F(2alpha) in human urine using liquid chromatographytandem mass spectrometry. Free Radic Biol Med, 34, 409-18.
  18. Lieberthal W, Triaca V, Levine J (1996). Mechanisms of death induced by cisplatin in proximal tubular epithelial cells: apoptosis vs. necrosis. Am J Physiol, 270, 700-8.
  19. Montuschi P, Barnes PJ, Roberts LJ (2004). Isoprostanes: markers and mediators of oxidative stress. FASEB J, 18, 1791-800.
  20. Montuschi P, Barnes PJ, Roberts LJ (2007). Insights into oxidative stress: the isoprostanes. Curr Med Chem, 14,703- 17.
  21. Moore K, Roberts LJ (1998). Measurement of lipid peroxidation. Free Radic Res, 28,659-71.
  22. Morrow JD, Hill KE, Burk RF, et al (1990). A series of prostaglandin $F_{2}$-like compounds are produced in vivo in humans by a non-cyclooxygenase free radical catalyzed mechanism. Proc Natl Acad Sci USA, 87, 9383-7.
  23. Morrow JD, Harris TM, Roberts LJ (1990). Noncyclooxygenase oxidative formation of a series of novel prostaglandins: analytical ramifications for measurement of eicosanoids. Anal Biochem, 184,1-10.Roberts LJ & Morrow JD (2000). Measurement of F(2)-isoprostanes as an index of oxidative stress in vivo. Free Radic Biol Med, 28, 505-13.
  24. Morrow JD, Roberts LJ (1994). Mass spectrometry of prostanoids: F2-isoprostanes produced by non-cyclooxygenase free radical-catalyzed mechanism. Methods Enzymol, 233, 163-74.
  25. Morrow JD, Roberts LJ (1996). The isoprostanes. Current knowledge and directions for future research. Biochem Pharmacol, 51, 1-9.
  26. Salahudeen A, Poovala V, Parry W, et al (1998). Cisplatin induces N-acetyl cysteine suppressible $F_{2}$-isoprostane production and injury in renal tubular epithelial cells. J Am Soc Nephrol, 9, 1448-55.
  27. Srivastava AN, Gupta A, Srivastava S, et al (2010). Cisplatin combination chemotherapy induces oxidative stress in advance non small cell lung cancer patients. APJCP, 11, 465-71.
  28. Villanueva MT (2011). Targeted therapies: Evolve and ... surrender! Nature Rev Clin Oncol, 8, 315.
  29. Yan W, Byrd GD, Ogden MW (2007). Quantitation of isoprostane isomers in human urine from smokers and nonsmokers by LC-MS/MS. J Lipid Res, 48, 1607-17.
  30. Zhang B, Saku K (2007). Control of matrix effects in the analysis of urinary $F_{2}$-isoprostanes using novel multidimensional solid-phase extraction and LC-MS/MS. J Lipid Res, 48, 733-44.
  31. Zieba M, Nowak D, Suwalski M, et al. (2001). Enhanced lipid peroxidation in cancer tissue homogenates in non-small cell lung cancer. Monaldi Arch Chest Dis, 56, 110-4.

Cited by

  1. Pu-erh Tea Powder Preventive Effects on Cisplatin-Induced Liver Oxidative Damage in Wistar Rats vol.15, pp.17, 2014,
  2. Effect of Zinc Supplementation on Antioxidant Defenses and Oxidative Stress Markers in Patients Undergoing Chemotherapy for Colorectal Cancer: a Placebo-Controlled, Prospective Randomized Trial vol.169, pp.1, 2016,
  3. Elevated exhalation of hydrogen peroxide in patients with non-small cell lung cancer is not affected by chemotherapy vol.22, pp.6, 2017,
  4. Nuclear magnetic resonance- and mass spectrometry-based metabolomics to study maleic acid toxicity from repeated dose exposure in rats vol.37, pp.12, 2017,